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Abstract Lung cancer causes more deaths in men and
women than any other cancer related disease. Currently,
few effective strategies exist to predict how patients will
respond to treatment. We evaluated the serum metabolomic
profiles of 25 lung cancer patients undergoing chemother-
apy ± radiation to evaluate the feasibility of metabolites as
temporal biomarkers of clinical outcomes. Serial serum
specimens collected prospectively from lung cancer
patients were analyzed using both nuclear magnetic reso-
nance (1H-NMR) spectroscopy and gas chromatography
mass spectrometry (GC–MS). Multivariate statistical
analysis consisted of unsupervised principal component
analysis or orthogonal partial least squares discriminant
analysis with significance assessed using a cross-validated
ANOVA. The metabolite profiles were reflective of the
temporal distinction between patient samples before during
and after receiving therapy (1H-NMR, p\ 0.001: and GC–
MS p\ 0.01). Disease progression and survival were
strongly correlative with the GC–MS metabolite data
whereas stage and cancer type were associated with 1H-
NMR data. Metabolites such as hydroxylamine, tridecan-1-
ol, octadecan-1-ol, were indicative of survival (GC–MS
p\ 0.05) and metabolites such as tagatose, hydroxy-
lamine, glucopyranose, and threonine that were reflective
of progression (GC–MS p\ 0.05). Metabolite profiles
have the potential to act as prognostic markers of clinical
outcomes for lung cancer patients. Serial 1H-NMR mea-
surements appear to detect metabolites diagnostic of tumor
pathology, while GC–MS provided data better related to
prognostic clinical outcomes, possibility due to physio-
chemical bias related to specific biochemical pathways.
These results warrant further study in a larger cohort and
with various treatment options.
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1 Introduction
Lung cancer is the leading cause of cancer related deaths in
both men and women in the world with 1.8 million patients
in 2012 and an estimated 1.6 million deaths. The majority
of lung cancers are diagnosed at an advanced stage at
which time all treatment is of palliative intent. Currently,
there are no prognostic or predictive biomarkers to help
ascertain which patients are most likely to benefit from
chemotherapy or radiation (Sawyers 2008).
Metabolic profiling has been reported in small series in
several types of cancers including lung (Fan et al. 2009;
Carrola et al. 2011; Yang et al. 2010; Jordan et al. 2010),
breast (Chen et al. 2009), ovarian (Odunsi et al. 2005),
prostate (Sreekumar et al. 2009), pancreatic (Bathe et al.
2011) and colorectal (Farshidfar et al. 2012). In studies of
lung cancer, most have explored the application of meta-
bolomics for diagnosis comparing samples from lung
cancer patients versus healthy volunteers (Fan et al. 2009;
Carrola et al. 2011; Yang et al. 2010) or samples from lung
cancer tissues versus surrounding non-cancerous tissues
(Hori et al. 2011). These studies have demonstrated that
many primary metabolites are found at higher levels in
lung cancer tissues/patients versus controls. Additionally,
others have examined and demonstrated that differences in
the levels of metabolites can distinguish between tumour
subtype (Jordan et al. 2010; Hori et al. 2011) and stage
(Hori et al. 2011). Wedge et al. (2011) evaluated plasma
from patients with small cell lung cancer and observed that
particular metabolites were associated with worse survival
outcomes. When 1H-NMR was used to evaluate metabolic
changes in 3LL lung cancer tumours grown subcutaneously
in mice who were treated with nitrosourea, alterations in
metabolites were observed in the growth inhibition and
growth recovery phase (Morvan and Demidem 2007).
More recently, Deja et al. (2014) using 1H-NMR reported
differences between COPD versus different stages of lung
cancer, also differences between early and late stage
NSCLC. Wen et al. (2013) utilized both GC–MS and LC–
MS to reveal metabolic differences between patients with
early stage adenocarcinoma of the lung and healthy con-
trols. Similarly, Lokhav et al. (2013) looked at discrimi-
nating metabolomic features between patients with any
stage of lung cancer versus healthy controls.
The majority of previous work concerns elucidation of
diagnostic metabolite patterns or markers, however there
have been only a few studies exploring the use of
metabolomics technologies as prognostic markers. Here we
examine metabolite profiles of lung cancer patients serially
during the course of treatment utilizing comprehensive
profiling by 1H-NMR and GC–MS. In this pilot study we
establish the feasibility of characterizing the serum meta-
bolic profiles of patients prior to, during, and in follow-up
after receiving standard chemotherapy and/or radiation. We
hypothesize that system-level analysis of serum metabo-
lites may provide a potentially non-invasive approach to
distinguish differences in physiologic state that may cor-
relate with clinical outcomes.
2 Materials and methods
2.1 Subjects and sample collection
Any patient with a histologic or cytologically confirmed
diagnosis of non-metastatic lung cancer undergoing stan-
dard chemotherapy ± radiation was eligible. Patients with
synchronous malignancies or prior chemotherapy or radi-
ation for any reason were excluded. Serum specimens were
collected at pre-specified time-points: prior to treatment,
during treatment, and at 6 months post-treatment. Blood
was collected by venipuncture, centrifuged at 15009g for
10 min at 4 C and separated within 24 h of collection then
stored at -80 C until 1H-NMR and GC–MS analysis.
Patients were not fasting at the time of blood sampling. In
total, analyzed 134 serum samples were analyzed.
2.2 1H-NMR and GC–MS measurements
2.2.1 NMR sample preparation and data acquisition
1H-NMR spectroscopy was performed using a protocol
previously described (Weljie et al. 2007). For NMR anal-
ysis, serum samples were thawed in ice. 350 ll of serum
sample were filtered through a prewashed Nanasep 3K
Omega Filter Eppendorf to remove high molecular weight
([3 kDa) compounds (e.g. large proteins, lipid complexes
etc.). The filtrate was then centrifuged and buffered to a pH
of 7.0 for analysis. Regular one-dimensional proton NMR
spectra were obtained using a 600-MHz Bruker Ultrashield
NMR spectrometer (Bruker Biospin, Milton, Canada). The
spectra were acquired using a standard pulse sequence that
had good water suppression characteristics and is com-
monly used for metabolite profiling of serum samples.
Relaxation delay of 1 s was used; t1 was set to 4 ls and tm
had a value of 100 ms. Initial samples for each batch were
shimmed to ensure half-height line width of\1.1 Hz for
the dimethyly-silapentane-sulphonate peak, calibrated to
0.0 ppm. Spectra were acquired with 1024 scans, then zero
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filled and Fourier transformed to 128 k data points using
the Chenomx NMRSuite processor (Weljie et al. 2006).
Additional 2-dimensional NMR experiments were per-
formed for the purpose of confirming chemical shift
assignments, including homonuclear total correlation
spectroscopy (2D 1H-1H TOCSY) and heteronuclear single
quantum coherence spectroscopy (2D 1H-13C HSQC),
using standard Bruker pulse programs.
2.2.2 GC–MS sample preparation and data acquisition
Sample preparation for the GC–MS consists of three basic
steps of deproteinization, methoxiamination and finally
derivatization. Deproteinization is able to remove the inter-
ference from proteins such as albumin, which are present in a
large concentration in blood. For GC–MS metabolite
extraction, samples are thawed on ice and 50 ll of sample
used for extraction using chloroform: methanol procedure.
Aqueous metabolites will be dried under vacuum, and then
derivatized usingmethoxyamine andMSTFA.Mass spectral
data was acquired using aWater GCT premier GC-TOF–MS
with anAgilent GC using a 30 mDB-5 column as previously
described (Farshidfar et al. 2012).
2.2.3 1H-NMR and GC–MS data processing and statistical
analysis
Raw data from 1H-NMR was processed and profiled using
Chenomx NMR Suite 7.1 to a library of 55 compounds. 1H-
NMR spectral data was evaluated using the strategy of
‘targeted profiling’ (Weljie et al. 2006). This allows
quantification of metabolite concentrations in the samples.
Raw data from GC–MS was imported to Metabolite
Detector for peak detection (Hiller et al. 2009).
The pre-processed data was exported to multi-variate sta-
tistical analytical software SIMCA-P 13? and analyzed with
principal component analysis (PCA) and orthogonal partial
least squares discriminant analysis (OPLS-DA). Univariate
scaling is applied to overcome the dominating effect of higher
intensity metabolite features. Thus scaling gives equal impor-
tance to all the components. Logarithmic transformation was
also done before analysis to reduce the effect of data skewness.
PCA was performed to check the unsupervised segre-
gation of the metabolome. OPLS-DA allowed us to dis-
criminate between the different variables concerning the
cancers in context. Model significance was assessed using a
cross-validated ANOVA with p B 0.05 considered signif-
icant. Variables were selected according to the VIP (vari-
able influence on projection) as previously described
(Weljie et al. 2007), which are reflective of the correlation
of the metabolites towards different response. VIP[ 1 was
considered significant.
To elucidate the relative changes of significant metabo-
lites before, during and after therapy, significance of analysis
of microarrays (SAM) with time course analysis was per-
formed (Zhang 2007). This analysis was applied indepen-
dently to both GC–MS and 1H-NMR metabolite datasets
(Denery et al. 2011).Metaboliteswere considered significant
with a corrected p value\0.05 and false discovery rate of
10 % to account for multiple testing.
We further investigated if specific clinical and outcome
factors, included variables such as cancer type (NSCLC
and SCLC), cancer staging (stages 1–4), time-point(s) of
sample collection, survival and progression could be pre-
dicted by the GC–MS and 1H-NMR datasets.
3 Results
3.1 Patient characteristics
Patient clinical and demographic characteristics of the
patients are listed in Table 1. 18 (72 %) had non-small cell
lung cancer, while 7 (18 %) had small cell lung cancer. The
majority of patients had stage III disease and underwent
treatment with concurrent chemoradiotherapy. The 2-year
overall survival for the group was 53 %.
3.2 Metabolomics analysis
3.2.1 Temporal metabolomic analysis distinguish sera
across treatment
Serum samples from each patient collected pre-treatment,
during therapy, and post-treatment were subject to both
NMR and GC–MS analysis. A total of 56 features were
Table 1 Patient demographics and clinical outcomes of patients with
small cell and non-small lung cancer
Patient characteristics
Age, median (range) 64 years (42–77)
Gender 60 % male
Smoking status 29 % current smokers
Tumour type
SCLC 7 (28 %)





Median DFS (range) 17 months (8–25)
2 year overall survival 53 %
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quantitatively assessed by NMR, and 106 features identi-
fied by GC–MS. Figure 1a is a box and whisker plot of the
multivariate scores of OPLS-DA analysis of GC–MS
metabolomic data from the three time-points. In this
analysis, the discriminant analysis was naı¨ve to the tem-
poral nature of the data, however a defined temporal
decrease in the scores from the first predicative component
is apparent. Analysis of the OPLS-DA loadings reveals that
the differences in timepoints was based on the differential
abundance of glucopyranose, citric acid, butanoic acid,
erythritol and ribitol between the three groups (N = 61,
CV-ANOVA p = 0.0046, R2 = 0.186, Q2 = 0.128)
(Table 2a.VIP[ 1). Figure 1b presents a similar analysis
of 1H-NMR metabolomic data. The differences were based
on the changing level of metabolites 2-aminobutyrate,
2-oxoglutarate, threonine, methionine, creatinine and
citrate between the three groups (N = 64 CV-ANOVA
p\ 0.001, R2 = 0.223, Q2 = 0.143) (Table 2b.VIP[ 1).
Interestingly metabolites such as threonine and citrate were
part of up the 1H-NMR metabolite data; were not picked by
the GCMS.
In order to further probe the temporal nature of the data,
we employed an analysis specific for time course data
(SAM), which utilized the repeated measurements within
individual patient samples. From the GCMS data, SAM
analysis identified 8 differentially abundant metabolites
across all treatment points (Fig. 1c). Of these named
metabolites included 2-hydroxybutanoic acid, glucopyra-
nose, citric acid, erythritol and ribitol. 1H-NMR metabolite
data was able to identify three significant metabolites
across the designated time points of sample collection.
These included taurine, threonine and creatinine (Fig. 1c).
3.3 Relationship of metabolite data to clinical
outcomes
3.3.1 GCMS metabolomic profiles facilitating prognostic
evaluation of survival and progression from pre-
treatment samples
From our preliminary O2-PLS models including all clinical






































Fig. 1 Metabolite bioprofiling facilitates discrimination between
three groups of patient sample collected at pre-treatment, mid-therapy
and post-treatment time points. Box and whisker plot reflective of
three distinct time points based on scores of OPLS-DA model of
a GC–MS and b NMR analysis of serum samples respectively;
Heatmap showing clustering of metabolites based on time for both
c NMR and GC–MS data respectively
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the two variables reflected by the GC–MS data (Fig. S1A).
We then constructed individual OPLS-DA models for these
covariates (Survival, Fig. S2B; Progression, Fig. S2C) based
on the metabolic samples of pre-treatment samples only, i.e.
naı¨ve to any chemotherapy or radiotherapy. The survival
model distinguishes the metabolite profile of patients who
had died during the course of treatment from those who had
survived treatment (N = 25, CV-ANOVA p = 0.0335,
R2 = 0.388, Q2 = 0.285). This distinction was based on
relative differences in metabolites such as tridecan-1-ol,
octadecan-1-ol and hydroxylamine in that were abundant in
patients who did not survive. Figure 2a is a box and whisker
plots that show the distribution of scores as a function of
deceased vs. survived therapy. A heatmap was constructed
using hierarchical clustering (Fig. 2b). This data illustrates
of metabolites such as glutamine, proline, valine, threonine
and tyramine being differentially abundant in the population
of patients who survived therapy where metabolites such as
hydroxylamine and octadecan-1-ol being at a higher con-
centration in patients who did not survive therapy.
Similarly, a significant OPLS-DA model was built
demonstrating a relationship between the GCMS metabolic
profile and disease progression (Fig. 2c; Fig. S2C; N = 25,
CV-ANOVA p\ 0.05, R2 = 0.397, Q2 = 0.333). This
difference was based on metabolites such as tagatose,
hydroxylamine, glucopyranose, and threonine. A heat map
illustrating the features involved in disease progression using
SAM analysis to distinguish groups (Fig. 2d) demonstrates
metabolites such as hydroxylamine are at relatively higher
concentration in the group of patients who were noted to
progress with the disease despite therapy, however glu-
copyranose and threonic acid were the metabolites was
found to be at a relatively higher level in patients inwhom the
disease did not show signs of progression.
Clinically, progression and survival are related events,
and thus in order to further understand the relationship
between metabolite reflective of survival and disease
progression a shared and unique structure (SUS) plot was
constructed (Fig. 2e). The metabolites that line up along
the diagonal running from the lower left corner to the
upper right corner are common to both the patient pro-
gression and survival model. These included metabolites
such as hydroxylamine (down-regulated), glucopyranose,
tagatose, glutamine, tyramine, and proline (up-regulated).
Metabolites such as phosphoric acid, glycine and
octadecanoic acid were unique to the disease survival
model. Our results thus indicate that a unique biomarker
profile is possible which distinguishes progression from
survival.
3.3.2 NMR metabolic profiles facilitates evaluation
of cancer staging and cancer type from pre-
treatment samples
Preliminary modeling of clinical covariates with quantita-
tive NMR-derived metabolic profiles indicated that cancer
stage and type were well reflected in the serum profiles. We
were able to facilitate discrimination in cancer staging
between cancer stages 1 and 2, versus stage 3 using 1H-
NMR metabolomic data (Supplemental Fig. 3A) (N = 24,
CV-ANOVA p\ 0.05, R2 = 0.474, Q2 = 0.314). This
was based on 8 metabolites such as 2-hydroxybutyrate,
2-oxoisocaproate, acetate, carnitine, 3-hydroxyisovalerate,
2-hydroxyisovalerate, glycerol and glycine. Summary of
the scores from this analysis (Fig. 3a) in which the distri-
bution is plotted according to the class i.e. stages 1 and 2,
versus stage 3; patients who were staged lower had a lower
score in comparison to patients with higher staging.
In a further subgroup analysis, we investigated the
metabolomic profiles of non-small cell lung (NSCLC)
cancer patients. Using 1H-NMR data we were able to dis-
tinguish sera based on cancer pathophysiology. Patients
with NSCLC could be discriminated into subtypes of
squamous and adenocarcinoma. OPLS-DA modeling was
able to discriminate between the two cancer sub-types
based on 19 differentially abundant spectral features
(Supplemental Fig. 3B) (N = 18, CV-ANOVA p\ 0.01,
R2 = 0.677, Q2 = 0.536). Figure 3b shows the box and
whisker plot plotted using metabolite scores based between
two classes of non small cell cancer i.e. squamous cell and
adenocarcinoma cell carcinoma respectively. Metabolites
such as 2-oxoisocaproate, 4-hydroxybutyrate, lysine,
Table 2 Metabolites from the GCMS and 1H-NMR data involved in
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arginine, dimethylamine, isobutyrate, 3-hydroxybutyrate,
acetate, asparagine, phenylalanine were relatively higher in
patients with adenocarcinoma. However, metabolites such
as pyruvate, lactate, valine, proline, isoleucine, histidine,
2-aminobutyrate, leucine and alloisoleucine were relatively
lower in the patients with adenocarcinoma.
4 Discussion
This pilot project aimed to examine the feasibility of
characterizing metabolomic profiles of lung cancer patients
serially over the course of treatment. We analyzed serum
specimens collected pre-treatment, at approximately the
mid-point of treatment and at 6-months follow-up. While
somewhat limited by the sample size of our study, we
observed that the metabolite profiles were clearly reflective
of both temporal and pathophysiological parameters.
Baseline samples naı¨ve to treatment are potentially pre-
dictive of crucial clinical parameters such as survival and
progression, and reflected tumor pathophysiology (squa-
mous cell vs. adenocarcinoma) and stage (1H-NMR,
p\ 0.05). These observations are consistent with those
made by others (Jordan et al. 2010; Hori et al. 2011). In
contrast to other studies, we collected serial samples and

















































Fig. 2 GC-MS metabolite bioprofiling facilitates prognostic evalua-
tion of clinical outcomes based on survival and disease progression.
a Box and whisker plot based on scores from OPLS-DA model of
patient survival at pretreatment as a function of the eventual survival
status: b Heat map showing clustering of metabolites with respect to
patient survival (c, d) Progression: c as in a, with samples stratified by
evidence of progression; d Heatmap showing progression-related
metabolites; e Shared and unique structure (SUS) Plot, highlighting
the strong relation between the two variables of disease progression
and survival. The metabolites that line up along the diagonal running
from the lower left corner to the upper right corner are common to
both the patient progression and survival model
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was reflective of the difference between the various time
points at which the samples were collected through the
treatment process. Such differences suggest that there may
be specific temporal shifts in metabolites during and after
which merit further examination.
We also observed that the metabolite profiles appear to
correlate with disease progression and survival (GC–MS
p\ 0.05). While Wedge et al. (2011), observed that par-
ticular metabolites were associated with worse survival
outcomes among SCLC patients, we examined the overall
metabolomic signature rather than identifying and quanti-
fying individual metabolites. Since lung cancer is an entity
involving differential metabolic changes in various path-
ways, the combinational approach of biomarker discovery
in the form of a profile could reflect the pathological
dynamics of the disease in a more comprehensive fashion.
One possible explanation for the segregation of
metabolite pools between those prognostic for survival and
those indicative of progression may lie in compartmental-
ization of biochemical processing and possible mitochon-
drial dysfunction. Metabolites from our study related to
survival, such as tridecan-1-ol and octadecan-1-ol are long
chain fatty alcohols which may result from oxidative pro-
cessing in peroxisomes or from dietary sources. These are
ketogenic substrates which are lower in deuterium content
(105–130 ppm) than cytosolic water (*155 ppm) (Duan
et al. 2002; Schmidt et al. 2003). In turn, mitochondrial
processing of ketogenic substrates leads to generation of
so-called ‘metabolic’ or ‘matrix’ water (i.e. water gener-
ated in the mitochondria) via beta-oxidation (Boros and
Somlyai 2015). This metabolic water is consequently rel-
atively depleted in deuterium, and this pool is ultimately
used for mitochondrial NADPH dependent macromolecu-
lar synthesis, including DNA. By this theory, hydrogen
bonding in DNA will be differentially impacted in patients
who use ketogenic substrates with lower deuterium content
due to isotope effects (Boros et al. 2014; Sobczyk et al.
2013). Conversely, pentose-cycle derived NADPH will
have a relatively elevated deuterium content and thus ele-
vation in markers from these non-ketogenic substrates
correlated with decreased survival. Elevated circulating
fatty alcohols as observed here in patients improved sur-
vival characteristics may serve as a marker of increased
deuterium depletion from ketogenic substrates, possibly
due to differing mitochondrial function. In fact, deuterium
depleted water has been shown to inhibit lung tumor
growth in vivo as well as reduce proliferation of A549 cell
lines with a concomitant increase in apoptosis (Cong
2010). In contrast, tagatose, hydroxylamine, glucopyranose
and threonine are glycogenic substrates were found to be
indicative of disease progression and do not impact deu-
terium loading for DNA stabilization to slow tumor
growth. The analytical platform dependence of our results
may be a result of an indirect bias in detection of ketogenic
metabolites by GC–MS.
Differences between our study and other metabolomic
studies in lung cancer could relate to variations in sample
collection. In the present study, we used serum instead of
plasma for our analyses. Previous studies (Yu et al. 2011;
Liu et al. 2010; Denery et al. 2011) have indicated that in
contrast to plasma, serum demonstrates a higher concen-
tration of metabolites and reduced background noise
making it suitable for biomarker discovery. We were not
able to control for external environmental factors that may
be confounding such as for diurnal variation, diet and
smoking status (Carrola et al. 2011; Psihogios et al. 2007).
However, comparison of changes in individual patients’
metabolomic profile over time should minimize the influ-
ence of intrinsic factors (gender, age, co-morbid medical
conditions).
Our study was also unique in that we utilized both
complementary technique of 1H-NMR and GC–MS; a
similar approach has been utilized by Zhang et al. (2012)



















Fig. 3 NMR metabolite bioprofiling facilitates evaluation of patho-
logical tumor characteristics. a Box and whisker plot reflective of
tumor staging: Scores from OPLS-DA analysis after baseline samples
were stratified into stages 1 and 2, versus 3; b Box and whisker plot
based on cancer cell type with sample stratified as non small cell lung
cancer type squamous cell and adenocarcinoma
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ability to draw any conclusion about whether 1H-NMR or
GC–MS might be the better tool as a whole, although our
finding point to each technology having stronger assess-
ments of different clinical parameters. Other groups have
used various analytic platforms including 1H-NMR (Car-
rola et al. 2011; Rocha et al. 2011), GC–MS (Hori et al.
2011; Wedge et al. 2011) and LC–MS (Wen et al. 2013).
Each technique affords different advantages and disad-
vantages. Whereas NMR requires less sample and sample
preparation, it is less sensitive and requires more expensive
instrumentation. Ultimately, no single analytical technique
can likely identify entire range of metabolites present in
biological samples and the combination of data from
multiple analytical platforms may be complementary.
In conclusion, it is feasible to characterize metabolomic
profiles from serum samples of lung cancer patients over
the course of their treatment. The relative heterogeneity of
the patients, treatments and sample collection in our small
pilot study limits our ability to draw any definitive con-
clusions. Therefore our findings should be interpreted as
preliminary and hypothesis generating. Nevertheless,
despite the small sample size, our preliminary findings
suggest there is variability in the metabolomic profile of
lung cancer patients that is associated with staging, prog-
nosis, and survival. Future studies are planned examining a
larger, more homogenous group of lung cancer patients
whose serial serum samples were prospectively collected
as part of a controlled clinical trial. With a larger sample
size we hope to more clearly characterize baseline meta-
bolomic profiles as well as any temporal changes in
metabolic patterns that occur over the course of treatment.
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